Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Antiviral Agents

Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices

Ondrej Martinec, Martin Huliciak, Frantisek Staud, Filip Cecka, Ivan Vokral, Lukas Cerveny
Ondrej Martinec
aDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Huliciak
aDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frantisek Staud
aDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Cecka
bDepartment of Surgery, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Vokral
aDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivan Vokral
Lukas Cerveny
aDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lukas Cerveny
DOI: 10.1128/AAC.00910-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

P-glycoprotein (ABCB1), an ATP-binding-cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug-drug interactions (DDIs). ABCB1 has been suggested to interact with many antivirals used to treat HIV and/or chronic hepatitis C virus (HCV) infections. Using bidirectional transport experiments in Caco-2 cells and a recently established ex vivo model of accumulation in precision-cut intestinal slices (PCIS) prepared from rat ileum or human jejunum, we evaluated the potential of anti-HIV and anti-HCV antivirals to inhibit intestinal ABCB1. Lopinavir, ritonavir, saquinavir, atazanavir, maraviroc, ledipasvir, and daclatasvir inhibited the efflux of a model ABCB1 substrate, rhodamine 123 (RHD123), in Caco-2 cells and rat-derived PCIS. Lopinavir, ritonavir, saquinavir, and atazanavir also significantly inhibited RHD123 efflux in human-derived PCIS, while possible interindividual variability was observed in the inhibition of intestinal ABCB1 by maraviroc, ledipasvir, and daclatasvir. Abacavir, zidovudine, tenofovir disoproxil fumarate, etravirine, and rilpivirine did not inhibit intestinal ABCB1. In conclusion, using recently established ex vivo methods for measuring drug accumulation in rat- and human-derived PCIS, we have demonstrated that some antivirals have a high potential for DDIs on intestinal ABCB1. Our data help clarify the molecular mechanisms responsible for reported increases in the bioavailability of ABCB1 substrates, including antivirals and drugs prescribed to treat comorbidity. These results could help guide the selection of combination pharmacotherapies and/or suitable dosing schemes for patients infected with HIV and/or HCV.

INTRODUCTION

HIV and hepatitis C virus (HCV) infections are a serious global health issue. It has been estimated that over 36 million people worldwide are HIV positive, with approximately 1 million of them dying every year (1). The total number of HCV-infected patients exceeds 80 million; HCV infection is directly associated with approximately 400,000 deaths annually (2). In developed countries such as the United States, the mortality due to HCV currently exceeds that due to HIV (3, 4).

Nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and C-C chemokine receptor type 5 (CCR5) antagonists are among the most widely used anti-HIV drugs. Recently approved pharmacotherapies for treating chronic HCV infections include directly acting inhibitors of HCV proteins controlling RNA replication, NS5A and the RNA-dependent RNA polymerase NS5B (5, 6). Anti-HIV and/or anti-HCV medication is always administered in regimens that combine antivirals with agents having different mechanisms of action (2, 7–9).

Up to 10% of HIV-infected patients refuse to continue antiretroviral therapy because of its side effects (8, 10–12). Intolerability is frequently due to drug-drug interactions (DDIs), which increase the plasma concentrations of antivirals or coadministered medications (8, 9, 13–20). The molecular mechanisms responsible for this increased bioavailability are often unclear.

Antivirals are administered orally and may therefore be subject to DDIs on membrane drug transporters in the intestinal barrier. P-glycoprotein (ABCB1) is an abundantly expressed drug transporter that controls cellular efflux to the intestinal lumen and thus governs the net intestinal uptake of its substrates (21–23). The International Transporter Consortium and the Food and Drug Administration have therefore both suggested that DDIs on ABCB1 may be clinically important (21, 24, 25). Because many antivirals are substrates and/or inhibitors of ABCB1 (15, 26–29), we hypothesized that they may induce or be affected by DDIs on intestinal ABCB1.

DDIs on the ABCB1 transporter cannot be rigorously evaluated directly in animals or humans because it is difficult to assign an observed DDI to a specific transporter (24). Therefore, experimental studies on DDIs involving antivirals on ABCB1 transporters have generally been based on in vitro observations (21, 30–38); there are few relevant data originating from more complex experimental setups in animals or human tissue (39, 40). This deficiency could be addressed using new techniques such as our recently developed ex vivo method for monitoring drug accumulation in rat- and human-derived precision-cut intestinal slices (PCIS). This method offers a testing throughput comparable to that achieved with the Caco-2 cell line, an in vitro model recommended by the Food and Drug Administration and European Medicines Agency (41–43). Importantly, PCIS retain the integrity of the intact fresh tissue as well as the physiological intestinal architecture and native enzymatic activity levels (42–44).

Here, we report the use of in vitro models of bidirectional transport across Caco-2 monolayers and ex vivo accumulation studies in rat- and human-derived PCIS to assess the inhibition of intestinal ABCB1-controlled efflux of rhodamine 123 (RHD123) by selected drugs, including NRTIs (abacavir, zidovudine, and tenofovir disoproxil fumarate [TDF]), NNRTIs (rilpivirine and etravirine), PIs (atazanavir, lopinavir, ritonavir, and saquinavir), CCR5 antagonists (maraviroc), NS5A inhibitors (daclatasvir and ledipasvir), and NS5B inhibitors (sofosbuvir).

RESULTS

Inhibitory effect of antiviral drugs on RHD123 transport in vitro.We initially verified the functional expression of ABCB1 in the Caco-2 cells by testing their capacity for bidirectional RHD123 (1 μM) transport in the presence and absence of CP100356 (2 μM). The rPapp values obtained in these experiments were 3.20 ± 0.32 and 1.02 ± 0.27, respectively, confirming the transporter’s presence and activity. Lopinavir and ledipasvir were the only antivirals that inhibited RHD123 efflux at the lowest tested concentration (5 μM). Ritonavir, saquinavir, atazanavir, and daclatasvir inhibited RHD123 efflux at a concentration of 20 μM. Maraviroc exhibited an inhibitory effect only at the highest tested concentration (100 μM). Abacavir (100 μM), zidovudine (100 μM), TDF (100 μM), rilpivirine (20 μM), etravirine (20 μM), and sofosbuvir (100 μM) did not affect RHD123 transport significantly (Table 1). We then compared the levels of ABCB1 inhibition induced by selected antivirals at the concentrations that caused the strongest inhibitory effects on bidirectional RHD123 transfer. This revealed that lopinavir (5 μM), ritonavir (20 μM), saquinavir (20 μM), and atazanavir (50 μM) inhibited ABCB1 more strongly than maraviroc (100 μM). Additionally, lopinavir (5 μM) and ritonavir (20 μM) were stronger inhibitors than daclatasvir (20 μM) (Fig. 1).

View this table:
  • View inline
  • View popup
TABLE 1

Effect of CP100356 and selected antiviral drugs on the transport ratio of RHD123 (1 μM) across Caco-2 cells

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Inhibition caused by antivirals tested at the concentrations causing the most significant effect on bidirectional transport of RHD123 (1 μM) across a monolayer of Caco-2 cells. (A) Calculated values of rPapp for RHD123 transport in the absence of inhibitors (dotted line) and in the presence (columns) of antivirals. (B) Multiple comparison of the inhibitory effects of antivirals. Data are presented as means ± SD (n = 3). Statistical analysis was performed using Student’s two-tailed t test (n = 3): n.s., not significant; *, P < 0.05; **, P < 0.01.

Inhibitory effects of antiviral drugs on RHD123 efflux in PCIS from rat ileum.We next tested the antivirals’ inhibitory effects on intestinal ABCB1 efflux in rat-derived PCIS. Treatment with CP100356 (2 μM) resulted in a 2.31-fold increase in RHD123 (10 μM) tissue accumulation, in accordance with earlier reports (43). This confirmed the functional expression of ABCB1 in the rat-derived PCIS. At concentrations of 5 μM, none of the antivirals inhibited ABCB1-controlled RHD123 efflux. Lopinavir, ritonavir, saquinavir, maraviroc, ledipasvir, and daclatasvir inhibit this efflux at concentrations of 20 μM, increasing the accumulation of RHD123 in the tissue by factors ranging from 1.37 ± 0.07 to 1.82 ± 0.26. Higher concentrations of ritonavir (50 and 100 μM) and ledipasvir (50 μM) resulted in more profound inhibition of RHD123 efflux, but higher concentrations of maraviroc (50 and 100 μM) did not. Atazanavir inhibited RHD123 efflux only at the highest tested concentration (50 μM) (Table 2). In keeping with the in vitro results, abacavir (100 μM), zidovudine (100 μM), TDF (100 μM), rilpivirine (20 μM), etravirine (20 μM), and sofosbuvir (100 μM) did not significantly inhibit RHD123 efflux in the rat PCIS (Table 2). We then compared inhibitory potency of the antivirals at the concentrations that caused the most profound inhibitory effect ex vivo. Only lopinavir (20 μM), ritonavir (100 μM), and daclatasvir (20 μM) inhibited rat intestinal ABCB1 more strongly than ledipasvir (50 μM) (Fig. 2).

View this table:
  • View inline
  • View popup
TABLE 2

Effect of the model inhibitor and selected antiviral drugs on accumulation of RHD123 (10 μM) over 2 h in the rat PCIS

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Inhibition of ABCB1-controled RHD123 efflux caused by antivirals tested at the concentrations causing the most significant increase in RHD123 (10 μM) accumulation over 2 h in rat PCIS. (A) Tissue RHD123 concentrations in the absence of inhibitors (dotted line) and in the presence of antivirals (columns). (B) Multiple comparison of inhibitory effects of antivirals. Data are presented as medians with interquartile ranges (n = 3). Statistical analysis was performed using the nonparametric Mann-Whitney test: n.s., not significant; *, P < 0.05.

Inhibitory effect of antiviral drugs on RHD123 efflux using PCIS from human intestine.Ex vivo experiments were performed using PCIS prepared from the jejunum of five donors to evaluate the antivirals’ inhibitory effects in a clinically relevant model. Antivirals were tested at the highest concentrations used in rat-derived PCIS. Lopinavir (50 μM), ritonavir (100) μM, saquinavir (20 μM), and atazanavir (50 μM) significantly inhibited RHD123 (10 μM) efflux in all of the intestinal samples. Daclatasvir (20 μM) inhibited RHD123 (10 μM) efflux in PCIS prepared from donors 3 and 5 only, while maraviroc (100 μM) and ledipasvir (50 μM) inhibited efflux in PCIS from donor 3 only (Table 3). It thus appears that there is some interindividual variability in the effects of these antivirals on human intestinal ABCB1.

View this table:
  • View inline
  • View popup
TABLE 3

Effect of the model inhibitor and selected antiviral drugs on the accumulation of RHD123 (10 μM) over 2 h in the human PCIS

Viability of rat and human PCIS exposed to the tested antivirals.Because the validity of accumulation studies using PCIS depends strongly on the tissue’s viability over the course of the experiment, we quantified the ATP content of the tissue samples, which is a stable and verified marker of the preservation of vital cellular processes (42, 43). The detected ATP concentrations in the rat PCIS (n = 3) were approximately 4 nmol · mg−1, while those in the human PCIS collected from five donors included in the study were between 3 and 4 nmol · mg−1. These values are consistent with those reported previously (42–44), and there were no statistically significant differences in the ATP contents of the tested samples (Fig. 3). It thus appears that the model inhibitor and antivirals did not affect the viability of the PCIS even at the highest tested concentrations.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

ATP content of the rat ileum (n = 3) (A) and human jejunum (n = 5) (B) after 2.5-h incubation in the presence of the studied antivirals at the highest concentrations used. Data are presented as medians with interquartile ranges. Statistical significance was assessed by nonparametric Kruskal-Wallis analysis followed by Dunn’s test. No statistically significant differences were found. TDF, tenofovir disoproxil fumarate.

DISCUSSION

HIV/HCV coinfection, age, the prescribed antiretroviral regimen, and polypharmacy are independent risk factors for DDIs (45, 46). It is therefore unsurprising that the prevalence of clinically relevant DDIs ranges from 14 to 41% (9, 45, 47). ABCB1 is a crucial determinant of intestinal absorption (22–24), but DDIs on this transporter may remain undiscovered during preclinical research and clinical trials (45). Consequently, there is great interest in methods for detecting ABCB1-mediated DDIs whose results can be extrapolated to the clinical environment; such methods are needed for both drugs in development and those that have already been launched commercially.

Rat and human PCIS have recently been put forward as reliable and efficient ex vivo models for studying the activity of transporters localized in enterocytes and for assessing the inhibitory potential of drugs (42–44). PCIS-based methods thus offer a superior capability for DDI detection while rivaling the throughput of in vitro cell-based models (42–44, 48–50).

In this work, we evaluated the ability of antivirals to inhibit intestinal ABCB1 by analyzing bidirectional transport of RHD123 across Caco-2 cells and measuring drug accumulation in rat- and human-derived PCIS (42–44). We selected antiviral drugs with different mechanisms of action and tested their inhibitory potential at concentrations up to the limit imposed by solubility or the concentration of maximal inhibitory effect. However, the tested concentrations of the antiviral drugs were lower than those likely to be achieved in the intestine following oral administration (51, 52). As a model ABCB1 substrate, we used RHD123 (42, 43), which is suitable for accumulation studies because it is easily detected and its efflux from enterocytes is not affected by metabolism (38, 53, 54). Our experimental designs of accumulation in PCIS were based on previously reported RHD123 concentrations (42, 43).

ABCB1 seems to be the transporter with the dominant influence on the pharmacokinetics of RHD123 (38, 54, 55). Other transporters such as the organic anion transporter peptide 1A2 and organic cation transporter 1 also reportedly contribute to RHD123 membrane transfer (56). However, their activity is unlikely to have influenced our results because the anion transporter peptide 1A2 exhibits little or no functional expression in the intestine (56) and none of the tested antivirals inhibits organic cation transporter 1 (26). Importantly, another crucial intestinal ABC transporter, breast cancer resistance protein, is not involved in RHD123 efflux (57).

Quenching effects on RHD123 fluorescence have been observed for atazanavir, lopinavir, saquinavir, and abacavir (38). Surprisingly, we observed significant increases in fluorescence in Hanks’ balanced salt solution (HBSS) buffer containing RHD123 (1 μM) upon adding 50 μM atazanavir (9%), 20 μM saquinavir (12%), 100 μM TDF (14%), 100 μM maraviroc (14%), or 100 μM sofosbuvir (15%). Only ledipasvir decreased the fluorescence (by 13% [data not shown]). In the bidirectional transport experiments, the same concentrations of the antiviral drugs were applied to the apical and basolateral compartments, and the concentrations of RHD123 in the receiving compartment were determined using a calibration curve based on reference solutions of the drugs. In RHD123 solutions containing an antiviral drug, the drug’s concentration had no detectable effect on the measured fluorescence. Therefore, the fluorescence measurements should not be significantly affected by potential changes in the drug concentrations of the apical and basolateral compartments due to ABC transporter activity (27, 32, 58, 59). In contrast to the results obtained in HBSS buffer, the fluorescence of RHD123 solutions in acetonitrile was independent of the presence of antivirals (data not shown). Therefore, a simple six-point calibration curve based on reference solutions without added antiviral drugs was used to determine RHD123 concentrations in PCIS-based experiments.

Using bidirectional RHD123 (1 μM) transport across Caco-2 cells, we demonstrated significant ABCB1-controlled transport that was abolished by a model ABCB1 inhibitor (CP100356). This confirmed the functional expression of ABCB1 in our cell line (Table 1). Subsequent experiments showed that lopinavir, ritonavir, saquinavir, atazanavir, daclatasvir, ledipasvir, and maraviroc all inhibit RHD123 efflux in Caco-2 cells, in keeping with previously reported in vitro studies (38, 53, 60–65). Of the tested antivirals, maraviroc (100 μM) and daclatasvir (20 μM) were the weakest inhibitors of RHD123 transport (Fig. 1).

Ex vivo accumulation studies were conducted in PCIS isolated from rat ileum and human jejunum. It has been shown that the functional expression of rat ABCB1 increases from the jejunum to the colon (61, 66), and ABCB1 model inhibitors affected RHD123 more strongly in the rat ileum than in other intestinal sections (42). In the human intestine, protein- and mRNA-level ABCB1 expression occurs predominantly in the jejunum and ileum (67, 68). ABCB1 activity seems to be higher in the ileum than the jejunum (43), but it was impossible to collect healthy segments of human ileum. The functional expression of ABCB1 in both rat and human experimental models was validated using CP100356, revealing that both models exhibited increases in RHD123 (10 μM) accumulation (Fig. 2 and Table 3) consistent with recently published data (42, 43).

Lopinavir, ritonavir, saquinavir, atazanavir, daclatasvir, ledipasvir, and maraviroc all strongly inhibited ABCB1 in rat-derived PCIS (Table 2). Of the tested antivirals, ritonavir (100 μM), lopinavir (20 μM), and daclatasvir (20 μM) had the greatest effects (Fig. 2). The ABCB1-inhibitory effect of ritonavir was previously demonstrated by in situ perfusion of murine intestines (39) and in murine whole-body pharmacokinetic studies (69, 70). We were unable to find any reports documenting the inhibition of animal-derived intestinal ABCB1 by any of the other tested drugs, however. Importantly, accumulation assays using rat-derived PCIS yielded similar results as in vitro bidirectional studies despite the previous finding that the inhibition of rat ABCB1 by antivirals can be affected to at least some extent by metabolic biodegradation in rat enterocytes, a phenomenon that does not occur in Caco-2 cells (71).

The inhibitory potential of selected antivirals was also tested in human-derived PCIS prepared from jejunum samples collected from five donors. Lopinavir (20 μM), ritonavir (100 μM), saquinavir (20 μM), and atazanavir (50 μM) exhibited significant inhibition of ABCB1 in intestinal samples from all five donors. Daclatasvir (20 μM) exhibited significant ABCB1 inhibition in PCIS from two donors, while maraviroc (100 μM) and ledipasvir (50 μM) abolished ABCB1 activity only in PCIS from one donor (Table 3). None of the tested compounds significantly affected the viability of both rat- and human-derived PCIS (Fig. 3).

It is important to note that ABCB1 activity is probably highest in the human ileum (43), and the antivirals were tested at concentrations that are probably lower than those occurring in the intestines of patients taking these drugs orally. The drugs’ inhibitory effects in clinical settings may therefore be even more pronounced than these results suggest. In accordance with our findings, a ritonavir-boosted atazanavir regimen reportedly increased the bioavailability of tenofovir by 91% when tenofovir was administered as the prodrug tenofovir alafenamide. Similarly, lopinavir boosted with ritonavir or atazanavir monotherapy increased the bioavailability of tenofovir by up to 32% and 37%, respectively, when tenofovir was administered as TDF (8). Tenofovir alafenamide and TDF are substrates of ABCB1 (8, 27, 51, 72), but tenofovir itself is not transported by either ABCB1 or other important drug efflux transporters such as breast cancer resistance protein and multidrug resistance-associated protein 2 (27). Moreover, tenofovir is not metabolized by cytochrome P450 (CYP450) isoenzymes, which are inhibited by lopinavir, atazanavir, or ritonavir (72, 73). Therefore, it can be hypothesized that intestinal ABCB1 inhibition is a key determinant of elevated plasma concentrations of tenofovir. Ledipasvir, daclatasvir, and maraviroc exhibited inconsistent inhibitory effects in the intestinal samples from the five donors (Table 3), while abacavir, TDF, and zidovudine exhibited no detectable inhibitory effects whatsoever (Tables 1 and 2). It is therefore unsurprising that (to our knowledge) there have been no reports of clinically relevant DDIs involving ledipasvir, daclatasvir, maraviroc, abacavir, TDF, or zidovudine that affect the bioavailability of coadministered ABCB1 substrates (8).

The variation in the reported ABCB1-inhibiting activity of certain drugs may be due to the use of different substrates in accumulation experiments as well as the use of different experimental techniques (74). We are therefore conducting follow-up experiments to test the effects of antivirals on intestinal efflux of digoxin, which is regarded as the standard ABCB1 probe for in vitro inhibitory studies (21, 24, 75). Lopinavir, atazanavir, daclatasvir, and ledipasvir reduced the efflux ratio of digoxin in bidirectional transport assays using Caco-2 cells, while abacavir had no significant effect, which is fully consistent with the results obtained using RHD123. In contrast to the findings obtained with RHD123, rilpivirine did inhibit ABCB1-mediated digoxin transport (data not shown). The experiments with digoxin are ongoing, and their results will be published in full elsewhere upon completion.

In conclusion, we have conducted the first complex study combining bidirectional transport assays and ex vivo accumulation in rat- and human-derived PCIS to evaluate DDIs involving clinically relevant drugs on intestinal ABCB1. Our results show that intestinal ABCB1 activity is not significantly inhibited by the anti-HIV and anti-HCV antiviral abacavir, zidovudine, TDF, etravirine, or rilpivirine but is inhibited by lopinavir, ritonavir, saquinavir, atazanavir, maraviroc, ledipasvir, and daclatasvir. Drugs in the latter group thus have a high potential to induce DDIs when administered orally. Our data may help explain the molecular mechanisms underpinning the elevated bioavailability of ABCB1 substrates, including antivirals and drugs prescribed to treat comorbidity following their oral administration. These results may also help guide the selection of combination pharmacotherapies and/or optimal dosing schemes for patients infected with HIV and/or HCV.

MATERIALS AND METHODS

Reagents and chemicals.RHD123 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Lopinavir, ritonavir, abacavir, zidovudine, TDF, rilpivirine, saquinavir, atazanavir, maraviroc, and etravirine were obtained from the NIH AIDS Reagent Program. Ledipasvir, daclatasvir, simeprevir, and sofosbuvir were obtained from Scintila (Jihlava, Czech Republic). The ABCB1 inhibitor CP100356 monohydrochloride (CP100356) (76), Dulbecco’s modified Eagle’s medium (DMEM), nonessential amino acid solution (NEAA), penicillin-streptomycin solutions, dimethyl sulfoxide (DMSO), fetal bovine serum (FBS), and the ATP bioluminescence assay kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hanks’ balanced salt solution (HBSS), William’s medium E containing l-glutamine (WME), and the bicinchoninic acid (BCA) protein assay kit were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Krebs‐Henseleit buffer was prepared as described by de Graaf et al. (44). All other reagents were of analytical grade.

Stock solution and test solution.CP100356 and all the antivirals were dissolved in DMSO, while RHD123 was dissolved in 99.9% ethyl alcohol (EtOH). The final concentration of DMSO or EtOH was 0.1% in all experiments. The highest tested concentrations of antivirals in the experimental settings were determined by their solubility in the chosen medium (38) and/or the criteria specified in the relevant paragraphs/tables. Stock solutions of test compounds were prepared in accordance with the manufacturer’s instructions; concentrations of antivirals in test solutions were not analytically determined (35, 38, 77).

Cell culture and growth condition.The colorectal adenocarcinoma (Caco-2) cell line (ATCC HTB-37) was obtained from the American Type Culture Collection and cultured in DMEM-complete high-glucose medium with l-glutamine, supplemented with 10% FBS and 1% NEAA. Cells were routinely cultured in antibiotic-free medium and incubated in a humidified incubator at 37°C in an atmosphere containing 5% CO2. Cells from passages 10 to 40 were used in all in vitro experiments.

Animals.Wistar male rats (340 to 560 g) were purchased from Velaz (Prague, Czech Republic) and maintained under standard conditions (12-h/12-h day/night cycles, water and pellets ad libitum). All experiments were approved by the Ministry of Education, Youth and Sport, Czech Republic (approval no. MSMT-8358/2016-13), and the procedures used were consistent with the recommendations given in both the Guide for the Care and Use of Laboratory Animals (78) and the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (79).

Human tissue samples.Intestinal samples (jejunum) were collected based on anamnesis from five donors, all nonsmokers (summarized in Table 4). After receiving written informed patient consent as approved by the local research ethics committee (approval no. 201511 S26P), the samples were collected at the University Hospital in Hradec Kralove, Czech Republic during pancreaticoduodenectomy procedures. The donors had not been administered drugs known to cause upregulation of ABCB1.

View this table:
  • View inline
  • View popup
TABLE 4

Characteristics of the human intestine donors

In vitro bidirectional permeability assays.Transport assays were performed using microporous polycarbonate membrane filters (0.4-μm pore size, 12-mm diameter; Transwell 3401; Costar, Corning, NY) together with Caco-2 cells as previously described (40). The cells were seeded at a density of 3 × 105 cells per insert and cultured for 21 days in standard cultivation medium containing 1% penicillin-streptomycin. The medium was changed three times a week, during which transepithelial electrical resistance (TEER) across cell monolayers was routinely measured using a Millicell-ERS instrument (Millipore Corporation, Bedford, MA) (40). TEER values before the start of the experiment ranged from 1,100 to 1,900 Ω · cm2, in keeping with previous reports (53, 80). For the bidirectional permeability assay, an HBSS buffer was used. The pH in the apical (A) compartment was adjusted to 6.5 using a methanesulfonic acid solution, while that of the buffer in the basolateral (B) compartment was adjusted to 7.4 using HEPES (81). To improve the reproducibility of the results, the receiver compartment always contained 1% bovine serum albumin as previously recommended (54, 81). All wells were preincubated for 30 min with the appropriate transport buffer containing the model inhibitor CP100356 or a tested antiviral drug (40, 81–83). The assay was initiated by adding fresh buffer containing RHD123 (1 μM) and the appropriate inhibitor or tested antiviral drug into the donor compartment (compartment A for A→B transport and compartment B for B→A transport). Samples (200 μl) were collected after 1 and 2 h from the receiver compartment; after this was done the first time, fresh receiver solution was added to the receiver compartment to maintain the original volume (81, 84). The A→B and B→A transports were evaluated in terms of an apparent permeability coefficient (Papp) calculated using the equation Papp = (dC/dt) × Vr/(A × C0), where dC/dt is the change in concentration over time measured during the linear phase of transport over 1 h, Vr is the volume of the receiver well in milliliters, A is the area of the membrane in square centimeters, and C0 is the initial concentration in the donor compartment. The efflux ratio (rPapp) was then calculated using the equation rPapp = (Papp B→A)/(Papp A→B) (51).

Ex vivo accumulation experiments in rat PCIS prepared from the ileum.PCIS assays were performed as previously described (42, 44). Briefly, Wistar male rats were anesthetized with ether and then sacrificed by cervical spine dislocation, after which the intestine was removed and placed in a cold oxygenated (carbogen gas, 95% O2 and 5% CO2) Krebs-Henseleit buffer as previously described (44). After cleaning and preparing the tissue, the intestine was filled with an agarose solution (3% [wt/vol] agarose in 0.9% NaCl solution, 37°C) and embedded into a block of agarose using a tissue embedding unit (44). Tissue-containing slices approximately 250 μm thick were then cut from this block using a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA). The slices were preincubated for 30 min in a 24-well plate with each well containing 500 μl of WME supplemented with glucose (25 mM) and the appropriate antiviral drugs. After preincubation, the slices were transferred into the same medium containing a cocktail of RHD123 (10 μM) with the model inhibitor or one of the chosen drugs and then incubated for 2 h. The length of incubation was chosen based on previous measurements of the model inhibitor’s effect on RHD123 uptake over incubations of 1 and 2 h (data not shown). Both incubation steps were performed in a humidified atmosphere of 80% O2 and 5% CO2 at 37°C (42, 44). Accumulation was halted after 2 h by washing the slices twice with cold (4°C) Krebs‐Henseleit buffer.

Ex vivo accumulation experiments in human PCIS prepared from the jejunum.The ex vivo accumulation assays were performed as described previously (43, 44). Immediately after surgery, the resected morphologically healthy part of the human intestine was placed into a cold (4°C) Krebs‐Henseleit buffer oxygenated with carbogen gas as previously reported (44). Mucosa was separated from the muscularis layer, dissected into fragments measuring approximately 5 by 20 mm, and then embedded in a 3% agarose solution (3% [wt/vol] in 0.9% NaCl, 37°C). PCIS of approximately 300-μm thickness were cut using a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) (43). The slices were preincubated for 30 min in the presence of the antiviral drugs in WME (43) and then transferred into a WME incubation medium containing RHD123 at a concentration of 10 μM (43) with the appropriate inhibitors. Both incubation steps were performed in a humidified atmosphere of 80% O2 and 5% CO2 at 37°C (43, 44). Accumulation was halted after 2 h by washing the slices twice with cold (4°C) Krebs‐Henseleit buffer.

RHD123 quantification.The concentration of RHD123 was quantified with a Tecan Infinite 200 M plate reader (Tecan Group, Männedorf, Switzerland), using excitation and emission wavelengths of 485 nm and 530 nm, respectively. RHD123 concentrations in samples collected from Caco-2 experiments were determined directly in HBSS buffer. Those in PCIS samples were assessed in supernatants prepared by adding 600 μl of acetonitrile solution (acetonitrile/water ratio, 2:1) and approximately 300 mg of glass minibeads (diameter, 1.25 to 1.65 mm; Carl Roth, Karlsruhe, Germany) to each slice and then homogenizing the tissue with a FastPrep24 5G minibead beater (MP Biomedicals, Santa Ana, CA, USA; 6.0 m/s, 2 times for 45 s each). Samples were then centrifuged (10 min; 7,800 × g), and the supernatant was collected for the analysis. Concentrations of RHD123 in samples collected from PCIS-based experiments were determined using a six-point calibration curve (concentrations, 0.000 μM, 0.0625 μM, 0.125 μM, 0.250 μM, 0.500 μM, and 1.000 μM) in acetonitrile solution. Six-point calibration curves for use with the bidirectional transport data were generated by analyzing samples prepared in HBSS buffer containing a tested antiviral drug at the appropriate concentration. RHD123 concentrations determined in PCIS were normalized against the protein content of the pellets obtained during centrifugation. The pellets were dried overnight at 37°C and then solubilized in 200 μl of 5 M NaOH for 24 h. Milli-Q water (800 μl) was then added to the samples to achieve an NaOH concentration of 1 M. The protein content of the processed samples was determined using a BCA protein kit (Thermo Fisher Scientific, Waltham, MA, USA).

Analysis of rat and human PCIS viability.The viability of the rat and human PCIS was evaluated by intracellular ATP concentration analysis as described previously (42, 43, 85). ATP concentrations were measured using the ATP bioluminescence assay kit CLS II (Roche, Mannheim, Germany). Measurements on PCIS were performed after a 2.5-h incubation with RHD123 (10 μM) and also after incubation with RHD123 (10 μM) and the model inhibitor or an antiviral drug.

Statistical analyses.The statistical significance of the data from the in vitro and human ex vivo experiments was assessed using Student’s two-tailed t test. Statistical analysis of the rat ex vivo experiments was performed using nonparametric two-tailed unpaired Mann-Whitney tests. The statistical significance of differences in the measured ATP concentrations was assessed using nonparametric Kruskal-Wallis analysis followed by Dunn’s test. All data were processed using GraphPad Prism 7.04 (GraphPad Software, Inc., San Diego, CA, USA).

ACKNOWLEDGMENTS

This research was financially supported by the Czech Science Foundation (GACR 18-07281Y), by the grant agency of Charles University (GAUK 1600317 and SVV 260 414), and by the project EFSA-CDN (no. CZ.02.1.01/0.0/0.0/16_019/0000841) cofunded by ERDF.

Ondrej Martinec contributed to the experimental design, performed and analyzed the in vitro cell-based experiments and the ex vivo accumulation experiments in PCIS, and helped write the manuscript. Martin Huliciak participated in the execution of the experiments and data analysis. Frantisek Staud contributed to the study’s conception and manuscript revision. Filip Cecka selected patients, performed small intestine resections, and contributed to manuscript revision. Ivan Vokral contributed to experimental design, performed and analyzed the in vitro cell-based experiments and ex vivo accumulation experiments in PCIS, helped write the manuscript, and contributed to the acquisition of financial support. Lukas Cerveny contributed to the experimental design, data analysis, and acquisition of financial support and contributed substantially to the writing of the manuscript. All authors have read and approved the final version of the manuscript.

FOOTNOTES

    • Received 3 May 2019.
    • Returned for modification 24 May 2019.
    • Accepted 30 August 2019.
    • Accepted manuscript posted online 3 September 2019.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    World Health Organization. 2019. HIV/AIDS. http://www.who.int/hiv/data/en/. Accessed 7 February 2019.
  2. 2.↵
    World Health Organization. 2019. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 7 February 2019.
  3. 3.↵
    1. Klevens RM,
    2. Hu DJ,
    3. Jiles R,
    4. Holmberg SD
    . 2012. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 55:S3–S9. doi:10.1093/cid/cis393.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Centers for Disease Control and Prevention. 2019. Hepatitis C kills more Americans than any other infectious disease. https://www.cdc.gov/media/releases/2016/p0504-hepc-mortality.html. Accessed 7 February 2019.
  5. 5.↵
    1. Nováková L,
    2. Pavlík J,
    3. Chrenková L,
    4. Martinec O,
    5. Červený L
    . 2018. Current antiviral drugs and their analysis in biological materials-part II: antivirals against hepatitis and HIV viruses. J Pharm Biomed Anal 147:378–399. doi:10.1016/j.jpba.2017.07.003.
    OpenUrlCrossRef
  6. 6.↵
    1. Nováková L,
    2. Pavlík J,
    3. Chrenková L,
    4. Martinec O,
    5. Červený L
    . 2018. Current antiviral drugs and their analysis in biological materials-part I: antivirals against respiratory and herpes viruses. J Pharm Biomed Anal 147:400–416. doi:10.1016/j.jpba.2017.06.071.
    OpenUrlCrossRef
  7. 7.↵
    AASLD/IDSA HCV Guidance Panel. 2015. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954. doi:10.1002/hep.27950.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Panel on Antiretroviral Guidelines for Adults and Adolescents. 2019. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 24 April 2019.
  9. 9.↵
    1. Garrison KL,
    2. German P,
    3. Mogalian E,
    4. Mathias A
    . 2018. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos 46:1212–1225. doi:10.1124/dmd.117.079038.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Muller F,
    2. Fromm MF
    . 2011. Transporter-mediated drug-drug interactions. Pharmacogenomics 12:1017–1037. doi:10.2217/pgs.11.44.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Marzolini C,
    2. Elzi L,
    3. Gibbons S,
    4. Weber R,
    5. Fux C,
    6. Furrer H,
    7. Chave JP,
    8. Cavassini M,
    9. Bernasconi E,
    10. Calmy A,
    11. Vernazza P,
    12. Khoo S,
    13. Ledergerber B,
    14. Back D,
    15. Battegay M
    , Swiss HIV Cohort Study. 2010. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 15:413–423. doi:10.3851/IMP1540.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Nachega JB,
    2. Hsu AJ,
    3. Uthman OA,
    4. Spinewine A,
    5. Pham PA
    . 2012. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 26(Suppl 1):S39–S53. doi:10.1097/QAD.0b013e32835584ea.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Goodlet KJ,
    2. Zmarlicka MT,
    3. Peckham AM
    . 2019. Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. CNS Spectr 24:287–312. doi:10.1017/S109285291800113X.
    OpenUrlCrossRef
  14. 14.↵
    1. Poizot-Martin I,
    2. Naqvi A,
    3. Obry-Roguet V,
    4. Valantin MA,
    5. Cuzin L,
    6. Billaud E,
    7. Cheret A,
    8. Rey D,
    9. Jacomet C,
    10. Duvivier C,
    11. Pugliese P,
    12. Pradat P,
    13. Cotte L,
    14. Hepadat A
    . 2015. Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS One 10:e0141164. doi:10.1371/journal.pone.0141164.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Kaur K,
    2. Gandhi MA,
    3. Slish J
    . 2015. Drug-drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications. Infect Dis Ther 4:159–172. doi:10.1007/s40121-015-0061-2.
    OpenUrlCrossRef
  16. 16.↵
    1. Dooley KE,
    2. Flexner C,
    3. Andrade AS
    . 2008. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 198:948–961. doi:10.1086/591459.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. McIlleron H,
    2. Meintjes G,
    3. Burman WJ,
    4. Maartens G
    . 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196(Suppl 1):S63–S75. doi:10.1086/518655.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Cihlar T,
    2. Ray AS,
    3. Laflamme G,
    4. Vela JE,
    5. Tong L,
    6. Fuller MD,
    7. Roy A,
    8. Rhodes GR
    . 2007. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12:267–272.
    OpenUrlPubMedWeb of Science
  19. 19.↵
    1. Ouwerkerk-Mahadevan S,
    2. Snoeys J,
    3. Peeters M,
    4. Beumont-Mauviel M,
    5. Simion A
    . 2016. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet 55:197–208. doi:10.1007/s40262-015-0314-y.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Rathbun RC,
    2. Liedtke MD
    . 2011. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 3:745–781. doi:10.3390/pharmaceutics3040745.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Giacomini KM,
    2. Huang SM
    . 2013. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther 94:3–9. doi:10.1038/clpt.2013.86.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Oostendorp RL,
    2. Beijnen JH,
    3. Schellens J
    . 2009. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treatment Rev 35:137–147. doi:10.1016/j.ctrv.2008.09.004.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Varma MV,
    2. Sateesh K,
    3. Panchagnula R
    . 2005. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12–21. doi:10.1021/mp0499196.
    OpenUrlCrossRefPubMed
  24. 24.↵
    International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236. doi:10.1038/nrd3028.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Zamek-Gliszczynski MJ,
    2. Taub ME,
    3. Chothe PP,
    4. Chu X,
    5. Giacomini KM,
    6. Kim RB,
    7. Ray AS,
    8. Stocker SL,
    9. Unadkat JD,
    10. Wittwer MB,
    11. Xia C,
    12. Yee SW,
    13. Zhang L,
    14. Zhang Y
    , International Transporter Consortium. 2018. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin Pharmacol Ther 104:890–899. doi:10.1002/cpt.1112.
    OpenUrlCrossRef
  26. 26.↵
    1. Kis O,
    2. Robillard K,
    3. Chan GN,
    4. Bendayan R
    . 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–35. doi:10.1016/j.tips.2009.10.001.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Neumanova Z,
    2. Cerveny L,
    3. Ceckova M,
    4. Staud F
    . 2014. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS 28:9–17. doi:10.1097/QAD.0000000000000112.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Neumanova Z,
    2. Cerveny L,
    3. Ceckova M,
    4. Staud F
    . 2016. Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine. Biopharm Drug Dispos 37:28–38. doi:10.1002/bdd.1993.
    OpenUrlCrossRef
  29. 29.↵
    1. Neumanova Z,
    2. Cerveny L,
    3. Greenwood SL,
    4. Ceckova M,
    5. Staud F
    . 2015. Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reprod Toxicol 57:176–182. doi:10.1016/j.reprotox.2015.07.070.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Agarwal S,
    2. Pal D,
    3. Mitra AK
    . 2007. Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor. Int J Pharm 339:139–147. doi:10.1016/j.ijpharm.2007.02.036.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Bierman WF,
    2. Scheffer GL,
    3. Schoonderwoerd A,
    4. Jansen G,
    5. van Agtmael MA,
    6. Danner SA,
    7. Scheper RJ
    . 2010. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65:1672–1680. doi:10.1093/jac/dkq209.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Kim RB,
    2. Fromm MF,
    3. Wandel C,
    4. Leake B,
    5. Wood AJ,
    6. Roden DM,
    7. Wilkinson GR
    . 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294. doi:10.1172/JCI1269.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Konig SK,
    2. Herzog M,
    3. Theile D,
    4. Zembruski N,
    5. Haefeli WE,
    6. Weiss J
    . 2010. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65:2319–2328. doi:10.1093/jac/dkq324.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. van der Sandt IC,
    2. Vos CM,
    3. Nabulsi L,
    4. Blom-Roosemalen MC,
    5. Voorwinden HH,
    6. de Boer AG,
    7. Breimer DD
    . 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier. AIDS 15:483–491. doi:10.1097/00002030-200103090-00007.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Weiss J,
    2. Rose J,
    3. Storch CH,
    4. Ketabi-Kiyanvash N,
    5. Sauer A,
    6. Haefeli WE,
    7. Efferth T
    . 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238–245. doi:10.1093/jac/dkl474.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Weiss J,
    2. Weis N,
    3. Ketabi-Kiyanvash N,
    4. Storch CH,
    5. Haefeli WE
    . 2008. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 579:104–109. doi:10.1016/j.ejphar.2007.11.007.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Zembruski NC,
    2. Buchel G,
    3. Jodicke L,
    4. Herzog M,
    5. Haefeli WE,
    6. Weiss J
    . 2011. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 66:802–812. doi:10.1093/jac/dkq501.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Storch CH,
    2. Theile D,
    3. Lindenmaier H,
    4. Haefeli WE,
    5. Weiss J
    . 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573–1581. doi:10.1016/j.bcp.2007.01.027.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Holmstock N,
    2. Mols R,
    3. Annaert P,
    4. Augustijns P
    . 2010. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab Dispos 38:1407–1410. doi:10.1124/dmd.110.032771.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Reznicek J,
    2. Ceckova M,
    3. Ptackova Z,
    4. Martinec O,
    5. Tupova L,
    6. Cerveny L,
    7. Staud F
    . 2017. MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption. Antimicrob Agents Chemother 61:e00837-17. doi:10.1128/AAC.00837-17.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Prueksaritanont T,
    2. Chu X,
    3. Gibson C,
    4. Cui D,
    5. Yee KL,
    6. Ballard J,
    7. Cabalu T,
    8. Hochman J
    . 2013. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J 15:629–645. doi:10.1208/s12248-013-9470-x.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Li M,
    2. de Graaf IA,
    3. de Jager MH,
    4. Groothuis GM
    . 2015. Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors ex vivo. Toxicol In Vitro 29:1070–1078. doi:10.1016/j.tiv.2015.04.011.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Li M,
    2. de Graaf IA,
    3. de Jager MH,
    4. Groothuis GM
    . 2017. P-gp activity and inhibition in the different regions of human intestine ex vivo. Biopharm Drug Dispos 38:127–138. doi:10.1002/bdd.2047.
    OpenUrlCrossRef
  44. 44.↵
    1. de Graaf IA,
    2. Olinga P,
    3. de Jager MH,
    4. Merema MT,
    5. de Kanter R,
    6. van de Kerkhof EG,
    7. Groothuis GM
    . 2010. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 5:1540–1551. doi:10.1038/nprot.2010.111.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Molas E,
    2. Luque S,
    3. Retamero A,
    4. Echeverria-Esnal D,
    5. Guelar A,
    6. Montero M,
    7. Guerri R,
    8. Sorli L,
    9. Lerma E,
    10. Villar J,
    11. Knobel H
    . 2018. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary team. HIV Clin Trials 19:1–7. doi:10.1080/15284336.2017.1404690.
    OpenUrlCrossRef
  46. 46.↵
    1. Marzolini C,
    2. Back D,
    3. Weber R,
    4. Furrer H,
    5. Cavassini M,
    6. Calmy A,
    7. Vernazza P,
    8. Bernasconi E,
    9. Khoo S,
    10. Battegay M,
    11. Elzi L
    , Swiss HIV Cohort Study Members. 2011. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 66:2107–2111. doi:10.1093/jac/dkr248.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Kigen G,
    2. Kimaiyo S,
    3. Nyandiko W,
    4. Faragher B,
    5. Sang E,
    6. Jakait B,
    7. Owen A,
    8. Back D,
    9. Gibbons S,
    10. Seden K,
    11. Khoo SH
    , USAID-Academic Model for Prevention Treatment of HIV/AIDS. 2011. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One 6:e16800. doi:10.1371/journal.pone.0016800.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Kamiyama E,
    2. Sugiyama D,
    3. Nakai D,
    4. Miura S,
    5. Okazaki O
    . 2009. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dispos 37:1956–1962. doi:10.1124/dmd.109.027490.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Sun D,
    2. Lennernas H,
    3. Welage LS,
    4. Barnett JL,
    5. Landowski CP,
    6. Foster D,
    7. Fleisher D,
    8. Lee KD,
    9. Amidon GL
    . 2002. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19:1400–1416. doi:10.1023/a:1020483911355.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Vaessen SF,
    2. van Lipzig MM,
    3. Pieters RH,
    4. Krul CA,
    5. Wortelboer HM,
    6. van de Steeg E
    . 2017. Regional expression levels of drug transporters and metabolizing enzymes along the pig and human intestinal tract and comparison with Caco-2 cells. Drug Metab Dispos 45:353–360. doi:10.1124/dmd.116.072231.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Tong L,
    2. Phan TK,
    3. Robinson KL,
    4. Babusis D,
    5. Strab R,
    6. Bhoopathy S,
    7. Hidalgo IJ,
    8. Rhodes GR,
    9. Ray AS
    . 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51:3498–3504. doi:10.1128/AAC.00671-07.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Bode H,
    2. Lenzner L,
    3. Kraemer OH,
    4. Kroesen AJ,
    5. Bendfeldt K,
    6. Schulzke JD,
    7. Fromm M,
    8. Stoltenburg-Didinger G,
    9. Zeitz M,
    10. Ullrich R
    . 2005. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. Antivir Ther 10:645–655.
    OpenUrlPubMed
  53. 53.↵
    1. Perloff ES,
    2. Duan SX,
    3. Skolnik PR,
    4. Greenblatt DJ,
    5. von Moltke LL
    . 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764–770. doi:10.1124/dmd.104.002931.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Forster S,
    2. Thumser AE,
    3. Hood SR,
    4. Plant N
    . 2012. Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One 7:e33253. doi:10.1371/journal.pone.0033253.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Jouan E,
    2. Le Vee M,
    3. Denizot C,
    4. Da Violante G,
    5. Fardel O
    . 2014. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Fundam Clin Pharmacol 28:65–77. doi:10.1111/j.1472-8206.2012.01071.x.
    OpenUrlCrossRef
  56. 56.↵
    1. Yu J,
    2. Zhou Z,
    3. Tay-Sontheimer J,
    4. Levy RH,
    5. Ragueneau-Majlessi I
    . 2017. Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci 106:2312–2325. doi:10.1016/j.xphs.2017.04.004.
    OpenUrlCrossRef
  57. 57.↵
    1. Honjo Y,
    2. Hrycyna CA,
    3. Yan QW,
    4. Medina-Perez WY,
    5. Robey RW,
    6. van de Laar A,
    7. Litman T,
    8. Dean M,
    9. Bates SE
    . 2001. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Cerveny L,
    2. Ptackova Z,
    3. Durisova M,
    4. Staud F
    . 2018. Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: effect on transplacental disposition in rats. Reprod Toxicol 79:57–65. doi:10.1016/j.reprotox.2018.05.008.
    OpenUrlCrossRef
  59. 59.↵
    1. Tupova L,
    2. Ceckova M,
    3. Ambrus C,
    4. Sorf A,
    5. Ptackova Z,
    6. Gaborik Z,
    7. Staud F
    . 2019. Interactions between maraviroc and the Abcb1, Abcg2 and Abcc2 transporters: an important role in transplacental pharmacokinetics. Drug Metab Dispos 47:954. doi:10.1124/dmd.119.087684.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Shiraki N,
    2. Hamada A,
    3. Yasuda K,
    4. Fujii J,
    5. Arimori K,
    6. Nakano M
    . 2000. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull 23:1528–1531. doi:10.1248/bpb.23.1528.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Yumoto R,
    2. Murakami T,
    3. Nakamoto Y,
    4. Hasegawa R,
    5. Nagai J,
    6. Takano M
    . 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149–155.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Abel S,
    2. Back DJ,
    3. Vourvahis M
    . 2009. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14:607–618.
    OpenUrlPubMedWeb of Science
  63. 63.↵
    1. Gandhi Y,
    2. Eley T,
    3. Fura A,
    4. Li W,
    5. Bertz RJ,
    6. Garimella T
    . 2018. Daclatasvir: a review of preclinical and clinical pharmacokinetics. Clin Pharmacokinet 57:911–928. doi:10.1007/s40262-017-0624-3.
    OpenUrlCrossRef
  64. 64.↵
    1. Gritsenko D,
    2. Hughes G
    . 2015. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T 40:256–276.
    OpenUrl
  65. 65.↵
    1. Kis O,
    2. Zastre JA,
    3. Hoque MT,
    4. Walmsley SL,
    5. Bendayan R
    . 2013. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res 30:1050–1064. doi:10.1007/s11095-012-0942-y.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. MacLean C,
    2. Moenning U,
    3. Reichel A,
    4. Fricker G
    . 2008. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos 36:1249–1254. doi:10.1124/dmd.108.020859.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Drozdzik M,
    2. Groer C,
    3. Penski J,
    4. Lapczuk J,
    5. Ostrowski M,
    6. Lai Y,
    7. Prasad B,
    8. Unadkat JD,
    9. Siegmund W,
    10. Oswald S
    . 2014. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm 11:3547–3555. doi:10.1021/mp500330y.
    OpenUrlCrossRef
  68. 68.↵
    1. Englund G,
    2. Rorsman F,
    3. Ronnblom A,
    4. Karlbom U,
    5. Lazorova L,
    6. Grasjo J,
    7. Kindmark A,
    8. Artursson P
    . 2006. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269–277. doi:10.1016/j.ejps.2006.04.010.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Huisman MT,
    2. Smit JW,
    3. Wiltshire HR,
    4. Hoetelmans RM,
    5. Beijnen JH,
    6. Schinkel AH
    . 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806–813. doi:10.1124/mol.59.4.806.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Tomaru A,
    2. Takeda-Morishita M,
    3. Banba H,
    4. Takayama K
    . 2013. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. Drug Metab Pharmacokinet 28:144–152. doi:10.2133/dmpk.DMPK-12-RG-057.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Schmiedlin-Ren P,
    2. Thummel KE,
    3. Fisher JM,
    4. Paine MF,
    5. Lown KS,
    6. Watkins PB
    . 1997. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Mol Pharmacol 51:741–754. doi:10.1124/mol.51.5.741.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Begley R,
    2. Das M,
    3. Zhong L,
    4. Ling J,
    5. Kearney BP,
    6. Custodio JM
    . 2018. Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. J Acquir Immune Defic Syndr 78:465–472. doi:10.1097/QAI.0000000000001699.
    OpenUrlCrossRef
  73. 73.↵
    1. Wyen C,
    2. Fuhr U,
    3. Frank D,
    4. Aarnoutse RE,
    5. Klaassen T,
    6. Lazar A,
    7. Seeringer A,
    8. Doroshyenko O,
    9. Kirchheiner JC,
    10. Abdulrazik F,
    11. Schmeisser N,
    12. Lehmann C,
    13. Hein W,
    14. Schomig E,
    15. Burger DM,
    16. Fatkenheuer G,
    17. Jetter A
    . 2008. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75–82. doi:10.1038/sj.clpt.6100452.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    1. Jouan E,
    2. Le Vee M,
    3. Mayati A,
    4. Denizot C,
    5. Parmentier Y,
    6. Fardel O
    . 2016. Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay. Pharmaceutics 8:E12. doi:10.3390/pharmaceutics8020012.
    OpenUrlCrossRef
  75. 75.↵
    1. Rautio J,
    2. Humphreys JE,
    3. Webster LO,
    4. Balakrishnan A,
    5. Keogh JP,
    6. Kunta JR,
    7. Serabjit-Singh CJ,
    8. Polli JW
    . 2006. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786–792. doi:10.1124/dmd.105.008615.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Kalgutkar AS,
    2. Frederick KS,
    3. Chupka J,
    4. Feng B,
    5. Kempshall S,
    6. Mireles RJ,
    7. Fenner KS,
    8. Troutman MD
    . 2009. N-(3,4-dimethoxyphenethyl)-4–(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100, 356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci 98:4914–4927. doi:10.1002/jps.21756.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Weiss J,
    2. Theile D,
    3. Ketabi-Kiyanvash N,
    4. Lindenmaier H,
    5. Haefeli WE
    . 2007. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35:340–344. doi:10.1124/dmd.106.012765.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
  79. 79.↵
    Council of Europe. 1986. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. European treaty series no. 123. Council of Europe, Strasbourg, France.
  80. 80.↵
    1. Hellinger E,
    2. Veszelka S,
    3. Toth AE,
    4. Walter F,
    5. Kittel A,
    6. Bakk ML,
    7. Tihanyi K,
    8. Hada V,
    9. Nakagawa S,
    10. Duy TD,
    11. Niwa M,
    12. Deli MA,
    13. Vastag M
    . 2012. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 82:340–351. doi:10.1016/j.ejpb.2012.07.020.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Hubatsch I,
    2. Ragnarsson EG,
    3. Artursson P
    . 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2:2111–2119. doi:10.1038/nprot.2007.303.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Fredlund L,
    2. Winiwarter S,
    3. Hilgendorf C
    . 2017. In vitro intrinsic permeability: a transporter-independent measure of Caco-2 cell permeability in drug design and development. Mol Pharm 14:1601–1609. doi:10.1021/acs.molpharmaceut.6b01059.
    OpenUrlCrossRef
  83. 83.↵
    1. Li J,
    2. Volpe DA,
    3. Wang Y,
    4. Zhang W,
    5. Bode C,
    6. Owen A,
    7. Hidalgo IJ
    . 2011. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39:1196–1202. doi:10.1124/dmd.111.038075.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. de Souza J,
    2. Benet LZ,
    3. Huang Y,
    4. Storpirtis S
    . 2009. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 98:4413–4419. doi:10.1002/jps.21744.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. van de Kerkhof EG,
    2. Ungell AL,
    3. Sjoberg AK,
    4. de Jager MH,
    5. Hilgendorf C,
    6. de Graaf IA,
    7. Groothuis GM
    . 2006. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metab Dispos 34:1893–1902. doi:10.1124/dmd.106.011148.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices
Ondrej Martinec, Martin Huliciak, Frantisek Staud, Filip Cecka, Ivan Vokral, Lukas Cerveny
Antimicrobial Agents and Chemotherapy Oct 2019, 63 (11) e00910-19; DOI: 10.1128/AAC.00910-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices
Ondrej Martinec, Martin Huliciak, Frantisek Staud, Filip Cecka, Ivan Vokral, Lukas Cerveny
Antimicrobial Agents and Chemotherapy Oct 2019, 63 (11) e00910-19; DOI: 10.1128/AAC.00910-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

rhodamine 123
antiviral drugs
intestinal absorption
drug-drug interactions
P-glycoprotein
Caco-2 cells
precision-cut intestinal slices

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596